Two other recent studies also support that ILA is associated with shorter overall survival in patients with stage I NSCLC (median OS: 46.2 months vs. 121.92 months; p < 0.0001) and stage IV NSCLC (median OS: 9.95 months vs. 16.95 months; p = 0.0002).11, 15. The gene discussed is TNFRSF9; the disease is non-small cell lung carcinoma.